Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 11/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CTSG | P08311 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.39 |
| ▸ | FCER2 | P06734 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203656 | 1.00 | CAPN1 (0.50) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL8196251 | 1.00 | CAPN1 (0.50) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL14123223 | 0.89 | CAPN1 (0.48) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL14123427 | 0.89 | CAPN1 (0.48) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL8209423 | 0.89 | CAPN1 (0.48) | CAPN1CTSLCTSBLMNACTSG | |
| SCHEMBL14123434 | 0.88 | MC4R (0.41) | PSMB1PSMB5PSMB2FCER2MMP2 | |
| SCHEMBL14123248 | 0.88 | CAPN1 (0.46) | CAPN1CTSLCTSBCTSSPSMB1 | |
| SCHEMBL14123201 | 0.88 | MC4R (0.41) | PSMB1PSMB5PSMB2FCER2MMP2 | |
| SCHEMBL14123217 | 0.88 | CAPN1 (0.46) | CAPN1CTSLCTSBCTSSPSMB1 | |
| SCHEMBL14123020 | 0.88 | MC4R (0.41) | PSMB1PSMB5PSMB2FCER2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | SERPINB1, EPHX1, EPX | CAPN1 199/4885CTSL 95/4885CTSB 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.